First National Advisers LLC Sells 4,753 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

First National Advisers LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,750 shares of the specialty pharmaceutical company’s stock after selling 4,753 shares during the quarter. First National Advisers LLC’s holdings in Jazz Pharmaceuticals were worth $2,555,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Crossmark Global Holdings Inc. raised its holdings in shares of Jazz Pharmaceuticals by 23.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company’s stock worth $567,000 after purchasing an additional 970 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $625,000. Victory Capital Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 23.3% in the 3rd quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock worth $28,220,000 after purchasing an additional 47,807 shares during the period. CIBC Asset Management Inc bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $209,000. Finally, Natixis Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 7.6% in the 3rd quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock worth $2,544,000 after purchasing an additional 1,603 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:JAZZ opened at $137.96 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The firm has a fifty day moving average of $129.52 and a 200 day moving average of $120.81. The firm has a market capitalization of $8.38 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock worth $4,022,825. Corporate insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the topic of a number of research reports. Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Morgan Stanley reissued an “overweight” rating and set a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.